Coventry University Featured PhD Programmes
University of Liverpool Featured PhD Programmes
Newcastle University Featured PhD Programmes
King’s College London Featured PhD Programmes
Karlsruhe Institute of Technology Featured PhD Programmes

Defining novel G protein-coupled receptor targets in neurodegenerative disease

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  • Full or part time
    Dr S Bradley
    Prof A Tobin
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

This project is one of 9 four-year PhD Studentships funded by Medical Research Scotland (www.medicalresearchscotland.org.uk) to be delivered jointly by the named University and Company. The Studentship will provide the first-class academic and commercial training needed to equip the successful candidate for a science career in an increasingly competitive market.

"Defining novel G protein-coupled receptor targets in neurodegenerative disease" to be delivered by the University of Glasgow [Supervisors: Dr Sophie Bradley and Professor Andrew Tobin (both Institute of Molecular, Cell and Systems Biology)] and Heptares Therapeutics, soseiheptares.com/ [Company Supervisors Dr. Kirstie Bennett, Principal Scientist Molecular Pharmacology and Dr. Alastair Brown (Head of Translational Sciences)].

This project aims to improve the understanding of mechanisms leading to neurodegenerative disease, such as Alzheimer’s disease, and to identify potential novel therapeutic targets to slow/halt the progression of disease. Focussed on the Type 5 metabotropic glutamate (mGlu5) receptor, a member of the G protein-coupled receptor (GPCR) superfamily, this studentship will employ novel pharmacological entitities developed by Heptares Therapeutics together with mouse models of neurodegeneration to evaluate this receptor as a target for the modulation of neuroinflammation and progression of neurodegenerative diseases. This studentship will use a range of behavioural, biochemical and pharmacological analyses to deliver on this overall objective.

This PhD studentship is funded by Medical Research Scotland in conjunction with Heptares Therapeutics and will offer the opportunity to conduct a research placement at the Heptares in Cambridge (UK). This studentship will benefit from a high-quality training programme provided by the University of Glasgow plus travel and consumables budgets and payment of tuition fees. The successful candidate will receive an annual stipend in line with RC-UK rates, plus an additional annual stipend "top-up" of from the industrial partner.

Please note, your application may be shared with the funders of this PhD Studentship, Medical Research Scotland and Heptares Therapeutics.

Please note also, although requested in the application form, a research proposal is NOT required as part of this application.

Start date: October 2019

Funding Notes

Applications are invited from outstanding UK and EU students, who hold or expect to gain a first or upper second-class degree or equivalent.

PhD Studentship provides: an annual tax-free stipend of £17,500, increasing to £18,000 over the four years; tuition fees at UK/EU rates only; consumables; and contribution to travel expenses. International fees are not covered.

References

https://www.gla.ac.uk/researchinstitutes/biology/staff/sophiebradley/

How good is research at University of Glasgow in Biological Sciences?

FTE Category A staff submitted: 60.34

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities


FindAPhD. Copyright 2005-2019
All rights reserved.